What Has Been The Historical And Current Growth Of The Biologic & Biosimilar RA Drugs Market?
The biologic & biosimilar ra drugs market has seen considerable growth due to a variety of factors.
• The market size for biologic & biosimilar ra drugs has experienced robust growth in the past few years. This market is projected to expand from $13.99 billion in 2024 to $14.71 billion in 2025, experiencing a compound annual growth rate (CAGR) of 5.2%. This historic growth can be linked to factors such as adoption rates in the market, results of clinical trials, changes in market share, outcomes for long-term patients, and pricing tactics.
What are the Market Size and Expected Growth Rates for the Biologic & Biosimilar RA Drugs Market?
The Biologic & Biosimilar RA Drugs market is expected to maintain its strong growth trajectory in upcoming years.
• Growth predictions for the biologic & biosimilar ra drugs market are robust, with expectations to hit a size of $19.51 billion by 2029, advancing at a compound annual growth rate (CAGR) of 7.3%.
This expected growth over the forecast period can be credited to factors like enhanced biologic drug development, competitive market dynamics, evolving healthcare policies, patient predilections, and clinical research & development. Key market trends for the predicted timeframe include an upsurge in biosimilar market competition, the emergence of individualized medicine and precision therapy, advancements in drug transportation systems, emphasis on drug safety and effectiveness, and a patient-centered approach to healthcare.
Which Key Drivers Are Propelling The Biologic and Biosimilar RA Drugs Market's Growth?
The biologics and biosimilar RA drugs market is getting a significant push from a growing elderly population and a higher occurrence of rheumatoid arthritis. The term 'older population' pertains to individuals aged 60 years and older. Rheumatoid arthritis is an autoimmune illness wherein the individual's immune system strikes its own healthy cells and principally impacts the person's joints. People in their late years are more prone to contracting rheumatoid arthritis as their immune defense weakens with age. Biologics and biosimilar RA drugs come forth as highly effective treatment mediums for rheumatoid arthritis in contrast with traditional drugs. Notably, the World Health Organization (WHO), a Switzerland-based health agency of the United Nations, suggests in their 2020 records that nearly 1 billion people worldwide were aged 60 and over. This demographic could possibly escalate to 1.4 billion by 2030, and 2.1 billion by 2050. On another note, the Centers for Disease Control and Prevention, a U.S.-based government health agency, forecast that the total count of adults with arthritis in the USA could climb to 78.4 million by 2040, with around 34.6 million people potentially struggling with arthritis-induced activity limitations. Thus, the upsurge in the elderly populace coupled with rising RA incidents is propelling the momentum for the biologics and biosimilars RA drugs market.
What Are The Key Segments Within The Global Biologic and Biosimilar RA Drugs Market?
The biologic & biosimilar RA drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
Pre-Book The Biologic and Biosimilar RA Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Biologic and Biosimilar RA Drugs Market?
A prominent trend in the biologic & biosimilar RA drugs market is the emergence of new innovations. Primarily, companies in this market are focusing on the development of biosimilar treatments such as Dual Concentration Biosimilar Options that serve as cost-effective alternatives. In July 2023, Organon, an American healthcare firm, cooperated with Samsung Bioepis, a firm from South Korea with a specialization in biopharmaceuticals, to introduce HADLIMA, a Humira (adalimumab) biosimilar, in America. Available in both high and low concentrations, HADLIMA presents a solution for enhancing access and affordability for those suffering from autoimmune afflictions. The biosimilar product has an 85% price reduction from Humira, thereby extending access to patients. The Arthritis Foundation acknowledges HADLIMA for its autoinjector feature. A patient support scheme, HADLIMA For You, offers learning resources and co-payment support. HADLIMA, suitable for various conditions like rheumatoid arthritis and Crohn's disease, is offered in two varieties; citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), ensuring uninterrupted patient care.
Who Are the Key Players In The Biologic and Biosimilar RA Drugs Market?
Major companies operating in the biologic & biosimilar RA drugs market include:
• Samsung BioLogics Co. Ltd.
• Amgen Inc.
• Novo Nordisk A/S
• AbbVie Inc.
• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Merck & Co. Inc.
• Eli Lilly and Company
• Novartis AG
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• AstraZeneca PLC.
• Teva Pharmaceutical Industries Ltd.
• Fresenius Se & Co. KGaA
• Stada Arzneimittel AG
• Boehringer Ingelheim Pharmaceuticals Inc.
• Gedeon Richter Plc.
• La Roche Ltd.
• Regeneron Pharmaceuticals Inc.
• Bristol-Myers Squibb Company
• Dr. Reddy's Laboratories Ltd.
• Biogen Inc.
• Genentech Inc.
• GlaxoSmithKline plc
• Mylan N.V.
• Sandoz International GmbH
• Amneal Pharmaceuticals LLC
• Apotex Inc.
• Biocon Ltd.
• Coherus BioSciences Inc.
What Are The Regional Insights Into The Biologic and Biosimilar RA Drugs Market?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
